News25/Ratings6
News · 26 weeks57+150%
2025-11-092026-05-03
Mix1890d
- SEC Filings8(44%)
- Other6(33%)
- Insider2(11%)
- Analyst2(11%)
Latest news
25 items- SECSEC Form 424B3 filed by Anteris Technologies Global Corp.424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)
- SECAnteris Technologies Global Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
- PRAnteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM TrialMINNEAPOLIS and BRISBANE, Australia, April 28, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced it has secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare & Medicaid Services (CMS) national coverage policy. Eligible procedures performed at participating U.S. study sites are covered under the Transcatheter Aortic Valve Replacement (TAVR) National Coverage Determination 20.32. The CMS framework oper
- SECSEC Form 424B3 filed by Anteris Technologies Global Corp.424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)
- SECAnteris Technologies Global Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
- SECSEC Form 424B3 filed by Anteris Technologies Global Corp.424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)
- SECSEC Form EFFECT filed by Anteris Technologies Global Corp.EFFECT - Anteris Technologies Global Corp. (0002011514) (Filer)
- ANALYSTCantor Fitzgerald resumed coverage on Anteris Technologies Global Corp. with a new price targetCantor Fitzgerald resumed coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $15.00
- ANALYSTWells Fargo initiated coverage on Anteris Technologies Global Corp. with a new price targetWells Fargo initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $16.00
- SECSEC Form POS AM filed by Anteris Technologies Global Corp.POS AM - Anteris Technologies Global Corp. (0002011514) (Filer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Mcdonnell Matthew4 - Anteris Technologies Global Corp. (0002011514) (Issuer)
- SECAnteris Technologies Global Corp. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
- PRAnteris Reports 2025 Financial Results and Provides Corporate UpdateMINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the full year ended December 31, 2025, and provided a corporate update. 2025 Full Year Highlights & Recent Developments Initiated the global pivotal PARADIGM Trial, building on experience from successfully treating 130 patients with the DurAVR® THV, including de novo (first time) aortic stenosis cases, complex anatomies and valve-in-valve p
- SECSEC Form 10-K filed by Anteris Technologies Global Corp.10-K - Anteris Technologies Global Corp. (0002011514) (Filer)
- PRAnteris to Present at Healthcare Investor Conferences TD Cowen and BarclaysMINNEAPOLIS and BRISBANE, Australia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson will be presenting at both the TD Cowen 46th Annual Healthcare Conference and the Barclays 28th Annual Healthcare Conference. The details of each conference and how to access them are as follows: TD Cowen 46th Annual Healthcare Conference Date:Monday, March 2nd, 2026 (US time)Format:Fireside chat wi
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.SCHEDULE 13G/A - Anteris Technologies Global Corp. (0002011514) (Subject)
- INSIDERLarge owner L1 Capital Pty Ltd bought $28,750,000 worth of shares (5,000,000 units at $5.75) (SEC Form 4)4 - Anteris Technologies Global Corp. (0002011514) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.SCHEDULE 13G/A - Anteris Technologies Global Corp. (0002011514) (Subject)
- SECSEC Form SCHEDULE 13D filed by Anteris Technologies Global Corp.SCHEDULE 13D - Anteris Technologies Global Corp. (0002011514) (Subject)
- INSIDERNew insider Medtronic Plc claimed ownership of 15,652,173 shares (SEC Form 3)3 - Anteris Technologies Global Corp. (0002011514) (Issuer)
- SECSEC Form 424B3 filed by Anteris Technologies Global Corp.424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)
- SECAnteris Technologies Global Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
- PRAnteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital RaisesMINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has completed a $90 million strategic investment from Medtronic, plc (Galway, Ireland) (NASDAQ:MDT) (Medtronic), the world's largest medical technology company. The investment closed immediately following Anteris' underwritten offering of common stock, for a combined $320 million in gross proceeds, which supports execution of the global pivotal PARADIGM trial and advan
- PRAnteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common StockMINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the closing of its underwritten public offering (the "Offering") of 40,000,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares from the Company (the "Shares"). The Shares were sold at a public offering price of $5.75 per share. In addition, Anteris today announced the closing of its previously anno
- SECAnteris Technologies Global Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
AVR FAQ
6 questionsWhere does AVR stock trade?
Anteris Technologies Global Corp. (AVR) is listed on NASDAQ.What sector and industry is AVR in?
Anteris Technologies Global Corp. operates in the Health Care sector, Industrial Specialties industry.When did Anteris Technologies Global Corp. go public?
Anteris Technologies Global Corp. (AVR) completed its IPO in 2024.What are analysts saying about AVR?
Anteris Technologies Global Corp. has had 6 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $1500.00 price target on 2026-03-12. Recent price targets range from $900.00 to $2200.00.What companies are similar to AVR?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare AVR side-by-side with any of them on Quantisnow.How can I track AVR on Quantisnow?
Quantisnow aggregates Anteris Technologies Global Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVR to receive live email and push alerts on every new disclosure.